Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
  • Portal Login

AZD7442

  • October 15, 2020
  • Posted by: OptimizeIAS Team
  • Category: DPN Topics
No Comments

Subject: Science and tech

Context : Swedish-British drug giant AstraZeneca recently said it was moving an antibody combination developed for Covid-19 treatment into late-stage human trials.

The firm has also received around $486 million from the US government.

Concept :

About:

  • AZD7442, a similar class of the drug cocktail used to treat US President recently, is a combination of two long-acting monoclonal antibodies (LAAB).
  • AstraZeneca developed it using its proprietary technology with the aim of preventing Covid-19 infection for a long duration.
  • LAABs mimic natural antibodies, and a combination of LAABs could be “complementary” to vaccines as a prophylactic agent.
  • This means it could either be used on people for whom a vaccine may not be appropriate or it could be given as added protection for those at high-risk.
AZD7442 Science and tech

Recent Posts

  • Daily Prelims Notes 23 March 2025 March 23, 2025
  • Challenges in Uploading Voting Data March 23, 2025
  • Fertilizers Committee Warns Against Under-Funding of Nutrient Subsidy Schemes March 23, 2025
  • Tavasya: The Fourth Krivak-Class Stealth Frigate Launched March 23, 2025
  • Indo-French Naval Exercise Varuna 2024 March 23, 2025
  • No Mismatch Between Circulating Influenza Strains and Vaccine Strains March 23, 2025
  • South Cascade Glacier March 22, 2025
  • Made-in-India Web Browser March 22, 2025
  • Charting a route for IORA under India’s chairship March 22, 2025
  • Mar-a-Lago Accord and dollar devaluation March 22, 2025

About

If IAS is your destination, begin your journey with Optimize IAS.

Hi There, I am Santosh I have the unique distinction of clearing all 6 UPSC CSE Prelims with huge margins.

I mastered the art of clearing UPSC CSE Prelims and in the process devised an unbeatable strategy to ace Prelims which many students struggle to do.

Contact us

moc.saiezimitpo@tcatnoc

For More Details

Work with Us

Connect With Me

Course Portal
Search